Furthermore, serum TRAIL levels hold clinical significance, as evidenced in a study involving eighteen patients with refractory prostate cancer, where higher serum TRAIL levels at nine months correlated with improved clinical outcomes (75). The gene discussed is TNFSF10; the disease is Familial prostate cancer.